SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus drug candidate enters human safety testing
Disease control Recruiting nowThis early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to see if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug lev…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-phase trial tests a new treatment for adults with severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells from donated umbilical cord blood to target and attack faulty cells driving the disease. The study will enro…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that drive autoimmune diseases like lupus and scleroderma. The therapy is given as a one-time infusion and aims to reset …
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug CC312 tested for tough autoimmune cases
Disease control Recruiting nowThis early study is testing the safety of a new drug, CC312, in 6 adults with lupus, myositis, or systemic sclerosis that has come back or not responded to standard treatments. Participants receive increasing doses of CC312 by IV to see if it is safe and tolerable. The goal is to…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Experimental cell therapy takes on tough lupus cases
Disease control Recruiting nowThis study tests a new treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. About 29 adults will receive this cell therapy to see if it can safely put their lupus into remission. The goal is to contro…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Lupus drug may stop organ damage, new study hopes to prove
Disease control Recruiting nowThis study is testing whether the drug belimumab can prevent serious organ damage in people with lupus (SLE). Researchers will compare patients taking belimumab to those on standard treatments, using medical records and new follow-ups. About 684 adults with active lupus will be i…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Sponsor: Biomedical Research Foundation, Academy of Athens • Aim: Disease control
Last updated May 11, 2026 20:39 UTC